<DOC>
	<DOCNO>NCT02673489</DOCNO>
	<brief_summary>The purpose study determine whether 24 week Daclatasvir Sofosbuvir Ribavirin safe effective treatment genotype 3 hepatitis C infect patient liver cirrhosis .</brief_summary>
	<brief_title>A Study Daclatasvir Sofosbuvir With Ribavirin Subjects With Cirrhosis Genotype 3 Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>For information regard BristolMyers Squibb ( BMS ) Clinical Trial participation , please visit www.BMSStudyConnect.com Genotype 3 HCV HCV RNA â‰¥10000 IU ( International Unit ) /mL Compensated Liver Cirrhosis BMI 1840 kg/m2 Previously treat HCV never treat HCV Infection HCV Genotype 3 . Mixed infection genotype Evidence decompensated liver disease Previous exposure NS5A inhibitors Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>